Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 280

1.

Characteristics of prescription in 29 Level 3 Neonatal Wards over a 2-year period (2017-2018). An inventory for future research.

Gouyon B, Martin-Mons S, Iacobelli S, Razafimahefa H, Kermorvant-Duchemin E, Brat R, Caeymaex L, Couringa Y, Alexandre C, Lafon C, Ramful D, Bonsante F, Binson G, Flamein F, Moussy-Durandy A, Di Maio M, Mazeiras G, Girard O, Desbruyeres C, Mourdie J, Escourrou G, Flechelles O, Abasse S, Rosenthal JM, Pages AS, Dorsi M, Karaoui L, ElGellab A, Le Bail Dantec F, Yangui MA, Norbert K, Kugbe Y, Lorrain S, Pignolet A, Garnier EM, Lapillonne A, Mitanchez D, Jacqz-Aigrain E, Gouyon JB.

PLoS One. 2019 Sep 19;14(9):e0222667. doi: 10.1371/journal.pone.0222667. eCollection 2019.

2.

Population pharmacokinetics of ganciclovir after valganciclovir in renal transplant children.

Facchin A, Elie V, Benyoub N, Magreault S, Maisin A, Storme T, Zhao W, Deschenes G, Jacqz-Aigrain E.

Antimicrob Agents Chemother. 2019 Sep 16. pii: AAC.01192-19. doi: 10.1128/AAC.01192-19. [Epub ahead of print]

PMID:
31527022
3.

UPLC/MS/MS assay for the simultaneous determination of seven antibiotics in human serum-Application to pediatric studies.

Magréault S, Leroux S, Touati J, Storme T, Jacqz-Aigrain E.

J Pharm Biomed Anal. 2019 Sep 10;174:256-262. doi: 10.1016/j.jpba.2019.03.004. Epub 2019 Mar 7.

PMID:
31181488
4.

Population pharmacokinetic meta-analysis of individual data to design the first randomized efficacy trial of vancomycin in neonates and young infants.

Jacqz-Aigrain E, Leroux S, Thomson AH, Allegaert K, Capparelli EV, Biran V, Simon N, Meibohm B, Lo YL, Marques R, Peris JE, Lutsar I, Saito J, Nakamura H, van den Anker JN, Sharland M, Zhao W.

J Antimicrob Chemother. 2019 Aug 1;74(8):2128-2138. doi: 10.1093/jac/dkz158.

PMID:
31049551
5.

Melatonin Levels in Preterm and Term Infants and Their Mothers.

Biran V, Decobert F, Bednarek N, Boizeau P, Benoist JF, Claustrat B, Barré J, Colella M, Frérot A, Garnotel R, Graesslin O, Haddad B, Launay JM, Schmitz T, Schroedt J, Virlouvet AL, Guilmin-Crépon S, Yacoubi A, Jacqz-Aigrain E, Gressens P, Alberti C, Baud O.

Int J Mol Sci. 2019 Apr 27;20(9). pii: E2077. doi: 10.3390/ijms20092077.

6.

Body Surface Area-Based Dosing Regimen of Caspofungin in Children: a Population Pharmacokinetics Confirmatory Study.

Yang XM, Leroux S, Storme T, Zhang DL, de Beaumais TA, Shi HY, Yang YL, Wang XL, Zhao W, Jacqz-Aigrain E.

Antimicrob Agents Chemother. 2019 Jun 24;63(7). pii: e00248-19. doi: 10.1128/AAC.00248-19. Print 2019 Jul.

PMID:
30988148
7.

Population Pharmacokinetics and Dosing Optimization of Imipenem in Children with Hematological Malignancies.

Dong L, Zhai XY, Yang YL, Wang L, Zhou Y, Shi HY, Tang BH, Wu YE, Yang F, Wen L, Kong HX, Zhi LJ, Jacqz-Aigrain E, Zhao W.

Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e00006-19. doi: 10.1128/AAC.00006-19. Print 2019 Jun.

PMID:
30962334
8.

Population Pharmacokinetics and Dosing Optimization of Amoxicillin in Neonates and Young Infants.

Tang BH, Wu YE, Kou C, Qi YJ, Qi H, Xu HY, Leroux S, Huang X, Zhou Y, Zheng Y, Jacqz-Aigrain E, Shen AD, Zhao W.

Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e02336-18. doi: 10.1128/AAC.02336-18. Print 2019 Feb.

9.

Ophthalmic Insert versus Eye Drops for Mydriasis in Neonates: A Randomized Clinical Trial.

Bremond-Gignac D, Jacqz-Aigrain E, Abdoul H, Daruich A, Beresniak A, Baud O, Alberti C; on behalf of the CLAIR FO Study Group.

Neonatology. 2019;115(2):142-148. doi: 10.1159/000493723. Epub 2018 Nov 27.

PMID:
30481790
10.

Variability of ciprofloxacin pharmacokinetics in children: impact on dose range in sickle cell patients.

Facchin A, Bui S, Leroux S, Nacka F, Koehl B, Maksoud E, Fayon M, Jacqz-Aigrain E; with the assistance of the Paediatric Clinical Investigation Centres Pharmacology Group.

J Antimicrob Chemother. 2018 Dec 1;73(12):3423-3429. doi: 10.1093/jac/dky328.

PMID:
30203024
11.

Early target attainment of azithromycin therapy in children with lower respiratory tract infections.

Liu S, Zheng Y, Wu X, Xu B, Liu X, Feng G, Sun L, Shen C, Li J, Tang B, Jacqz-Aigrain E, Zhao W, Shen A.

J Antimicrob Chemother. 2018 Oct 1;73(10):2846-2850. doi: 10.1093/jac/dky273.

PMID:
30060209
12.

Population Pharmacokinetics and Dosing Optimization of Azithromycin in Children with Community-Acquired Pneumonia.

Zheng Y, Liu SP, Xu BP, Shi ZR, Wang K, Yang JB, Huang X, Tang BH, Chen XK, Shi HY, Zhou Y, Wu YE, Qi H, Jacqz-Aigrain E, Shen AD, Zhao W.

Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e00686-18. doi: 10.1128/AAC.00686-18. Print 2018 Sep.

13.

Transethnic, Genome-Wide Analysis Reveals Immune-Related Risk Alleles and Phenotypic Correlates in Pediatric Steroid-Sensitive Nephrotic Syndrome.

Debiec H, Dossier C, Letouzé E, Gillies CE, Vivarelli M, Putler RK, Ars E, Jacqz-Aigrain E, Elie V, Colucci M, Debette S, Amouyel P, Elalaoui SC, Sefiani A, Dubois V, Simon T, Kretzler M, Ballarin J, Emma F, Sampson MG, Deschênes G, Ronco P.

J Am Soc Nephrol. 2018 Jul;29(7):2000-2013. doi: 10.1681/ASN.2017111185. Epub 2018 Jun 14.

14.

Clinical trials in neonates: How to optimise informed consent and decision making? A European Delphi survey of parent representatives and clinicians.

Neyro V, Elie V, Thiele N, Jacqz-Aigrain E.

PLoS One. 2018 Jun 13;13(6):e0198097. doi: 10.1371/journal.pone.0198097. eCollection 2018.

15.

Aciclovir CSF concentration in children with viral encephalitis: is it adequate?

Sun SZ, Wang L, Wu YE, Ma GL, Yao BF, Dong L, Jacqz-Aigrain E, Shi ZR, Zhao W.

J Antimicrob Chemother. 2018 Sep 1;73(9):2582-2583. doi: 10.1093/jac/dky217. No abstract available.

PMID:
29878193
16.

Pharmacogenetics: Applications to Pediatric Patients.

Adam de Beaumais T, Jacqz-Aigrain E.

Adv Pharmacol. 2018;83:191-215. doi: 10.1016/bs.apha.2018.04.006. Epub 2018 May 17. Review.

PMID:
29801575
17.

Pharmacokinetics and safety of fluconazole and micafungin in neonates with systemic candidiasis: a randomized, open-label clinical trial.

Leroux S, Jacqz-Aigrain E, Elie V, Legrand F, Barin-Le Guellec C, Aurich B, Biran V, Dusang B, Goudjil S, Coopman S, Garcia Sanchez R, Zhao W, Manzoni P; FP7 TINN (Treat Infections in NeoNates) consortium.

Br J Clin Pharmacol. 2018 Sep;84(9):1989-1999. doi: 10.1111/bcp.13628. Epub 2018 Jun 21.

18.

Population pharmacokinetics and dosing optimization of cefathiamidine in children with hematologic infection.

Zhi LJ, Wang L, Chen XK, Zhai XY, Wen L, Dong L, Jacqz-Aigrain E, Shi ZR, Zhao W.

Drug Des Devel Ther. 2018 Apr 17;12:855-862. doi: 10.2147/DDDT.S160329. eCollection 2018.

19.

Capacities and Competences for Drug Evaluation in European Neonatal Intensive Care Units: A Survey and Key Issues for Improvement.

Elie V, Neyro V, Ha P, Aurich B, Leroux S, Jacqz-Aigrain E.

Am J Perinatol. 2018 May;35(6):589-598. doi: 10.1055/s-0038-1637766. Epub 2018 Apr 25.

PMID:
29695003
20.

Population pharmacokinetics of tacrolimus in children with nephrotic syndrome.

Hao GX, Huang X, Zhang DF, Zheng Y, Shi HY, Li Y, Jacqz-Aigrain E, Zhao W.

Br J Clin Pharmacol. 2018 Aug;84(8):1748-1756. doi: 10.1111/bcp.13605. Epub 2018 May 22.

21.

Principles and applications of pharmacometrics in drug evaluation in children.

Leroux S, Elie V, Zhao W, Magreault S, Jacqz-Aigrain E.

Therapie. 2018 Apr;73(2):165-170. doi: 10.1016/j.therap.2017.11.011. Epub 2018 Feb 16.

PMID:
29605146
22.

Drug evaluation in children 10years after the European pediatric regulation current challenges and perspectives.

Élie V, Leroux S, Kaguelidou F, Jacqz-Aigrain E.

Therapie. 2018 Apr;73(2):113-117. doi: 10.1016/j.therap.2017.11.006. Epub 2018 Feb 17.

PMID:
29580612
23.

Off-label use of tacrolimus in children with Henoch-Schönlein purpura nephritis: a pilot study.

Zhang DF, Hao GX, Li CZ, Yang YJ, Liu FJ, Liu L, Yuan XY, Li RH, Dong L, Dong Q, Jacqz-Aigrain E, Zhao W.

Arch Dis Child. 2018 Aug;103(8):772-775. doi: 10.1136/archdischild-2017-313788. Epub 2018 Mar 13.

PMID:
29535109
24.

Pharmacogenetics and application in pediatrics.

Neyro V, Jacqz-Aigrain E, Adam de Beaumais T.

Therapie. 2018 Apr;73(2):157-163. doi: 10.1016/j.therap.2017.11.010. Epub 2018 Feb 16. Review.

PMID:
29530313
25.

Pilot Study of Model-Based Dosage Individualization of Ganciclovir in Neonates and Young Infants with Congenital Cytomegalovirus Infection.

Dong Q, Leroux S, Shi HY, Xu HY, Kou C, Khan MW, Jacqz-Aigrain E, Zhao W.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e00075-18. doi: 10.1128/AAC.00075-18. Print 2018 May.

26.

Sequential analysis in neonatal research-systematic review.

Lava SAG, Elie V, Ha PTV, Jacqz-Aigrain E.

Eur J Pediatr. 2018 May;177(5):733-740. doi: 10.1007/s00431-018-3110-5. Epub 2018 Feb 16. Review.

PMID:
29453599
27.

Penetration of Cefotaxime into Cerebrospinal Fluid in Neonates and Young Infants.

Chen XK, Shi HY, Leroux S, Xu HY, Zhou Y, Zheng Y, Huang X, Li Y, Jacqz-Aigrain E, Zhao W.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02448-17. doi: 10.1128/AAC.02448-17. Print 2018 Apr.

28.

mRNA expression of drug metabolism enzymes and transporter genes at birth using human umbilical cord blood.

Neyro V, Elie V, Médard Y, Jacqz-Aigrain E.

Fundam Clin Pharmacol. 2018 Aug;32(4):422-435. doi: 10.1111/fcp.12357. Epub 2018 Mar 13.

PMID:
29436076
29.

Pharmacogenetics of post-transplant diabetes mellitus in children with renal transplantation treated with tacrolimus.

Lancia P, Adam de Beaumais T, Elie V, Garaix F, Fila M, Nobili F, Ranchin B, Testevuide P, Ulinski T, Zhao W, Deschênes G, Jacqz-Aigrain E.

Pediatr Nephrol. 2018 Jun;33(6):1045-1055. doi: 10.1007/s00467-017-3881-3. Epub 2018 Feb 4.

PMID:
29399716
30.

Population Pharmacokinetics of Cefotaxime and Dosage Recommendations in Children with Sickle Cell Disease.

Maksoud E, Koehl B, Facchin A, Ha P, Zhao W, Kaguelidou F, Benkerrou M, Mariani P, Faye A, Lorrot M, Jacqz-Aigrain E.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e00637-17. doi: 10.1128/AAC.00637-17. Print 2018 Apr.

31.

Population Pharmacokinetics and Dosing Optimization of Ceftazidime in Infants.

Shi ZR, Chen XK, Tian LY, Wang YK, Zhang GY, Dong L, Jirasomprasert T, Jacqz-Aigrain E, Zhao W.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02486-17. doi: 10.1128/AAC.02486-17. Print 2018 Apr.

32.

Developmental pharmacogenetics of CYP2C19 in neonates and young infants: omeprazole as a probe drug.

Zhao W, Leroux S, Biran V, Jacqz-Aigrain E.

Br J Clin Pharmacol. 2018 May;84(5):997-1005. doi: 10.1111/bcp.13526. Epub 2018 Mar 9.

33.

Adverse Events under Tacrolimus and Cyclosporine in the First 3 Years Post-Renal Transplantation in Children.

Lancia P, Aurich B, Ha P, Maisin A, Baudouin V, Jacqz-Aigrain E.

Clin Drug Investig. 2018 Feb;38(2):157-171. doi: 10.1007/s40261-017-0594-0.

PMID:
29236209
34.

Predicting CYP3A-mediated midazolam metabolism in critically ill neonates, infants, children and adults with inflammation and organ failure.

Brussee JM, Vet NJ, Krekels EHJ, Valkenburg AJ, Jacqz-Aigrain E, van Gerven JMA, Swart EL, van den Anker JN, Tibboel D, de Hoog M, de Wildt SN, Knibbe CAJ.

Br J Clin Pharmacol. 2018 Feb;84(2):358-368. doi: 10.1111/bcp.13459. Epub 2017 Nov 29.

35.

Growth Outcomes After GH Therapy of Patients Given Long-Term Corticosteroids for Juvenile Idiopathic Arthritis.

David H, Aupiais C, Louveau B, Quartier P, Jacqz-Aigrain E, Carel JC, Simon D.

J Clin Endocrinol Metab. 2017 Dec 1;102(12):4578-4587. doi: 10.1210/jc.2017-01455.

PMID:
29029101
36.

High Prevalence of Polycystic Ovary Syndrome in Type 1 Diabetes Mellitus Adolescents: Is There a Difference Depending on the NIH and Rotterdam Criteria?

Busiah K, Colmenares A, Bidet M, Tubiana-Rufi N, Levy-Marchal C, Delcroix C, Jacquin P, Martin D, Benadjaoud L, Jacqz-Aigrain E, Laborde K, Robert JJ, Samara-Boustani D, Polak M.

Horm Res Paediatr. 2017;87(5):333-341. doi: 10.1159/000471805. Epub 2017 Apr 24.

PMID:
28437788
37.

Pharmacogenetics of posttransplant diabetes mellitus.

Lancia P, Adam de Beaumais T, Jacqz-Aigrain E.

Pharmacogenomics J. 2017 Jun;17(3):209-221. doi: 10.1038/tpj.2017.1. Epub 2017 Mar 28. Review.

PMID:
28349930
38.

Drug versus placebo randomized controlled trials in neonates: A review of ClinicalTrials.gov registry.

Desselas E, Pansieri C, Leroux S, Bonati M, Jacqz-Aigrain E.

PLoS One. 2017 Feb 13;12(2):e0171760. doi: 10.1371/journal.pone.0171760. eCollection 2017.

39.

Dose evaluation of lamivudine in human immunodeficiency virus-infected children aged 5 months to 18 years based on a population pharmacokinetic analysis.

Janssen EJH, Bastiaans DET, Välitalo PAJ, van Rossum AMC, Jacqz-Aigrain E, Lyall H, Knibbe CAJ, Burger DM.

Br J Clin Pharmacol. 2017 Jun;83(6):1287-1297. doi: 10.1111/bcp.13227. Epub 2017 Feb 14.

40.

Dose-Finding Study of Omeprazole on Gastric pH in Neonates with Gastro-Esophageal Acid Reflux Using a Bayesian Sequential Approach.

Kaguelidou F, Alberti C, Biran V, Bourdon O, Farnoux C, Zohar S, Jacqz-Aigrain E.

PLoS One. 2016 Dec 21;11(12):e0166207. doi: 10.1371/journal.pone.0166207. eCollection 2016.

41.

A Computer Prescribing Order Entry-Clinical Decision Support system designed for neonatal care: results of the 'preselected prescription' concept at the bedside.

Gouyon B, Iacobelli S, Saliba E, Quantin C, Pignolet A, Jacqz-Aigrain E, Gouyon JB.

J Clin Pharm Ther. 2017 Feb;42(1):64-68. doi: 10.1111/jcpt.12474. Epub 2016 Nov 23.

PMID:
27882560
42.

A 6-Month Trial of the Efficacy and Safety of Triptorelin Pamoate (11.25 mg) Every 3 Months in Children with Precocious Puberty: A Retrospective Comparison with Triptorelin Acetate.

Zenaty D, Blumberg J, Liyanage N, Jacqz-Aigrain E, Lahlou N, Carel JC; Co-Investigators.

Horm Res Paediatr. 2016;86(3):188-195. Epub 2016 Sep 7.

43.

A Population and Developmental Pharmacokinetic Analysis To Evaluate and Optimize Cefotaxime Dosing Regimen in Neonates and Young Infants.

Leroux S, Roué JM, Gouyon JB, Biran V, Zheng H, Zhao W, Jacqz-Aigrain E.

Antimicrob Agents Chemother. 2016 Oct 21;60(11):6626-6634. doi: 10.1128/AAC.01045-16. Print 2016 Nov.

44.

Licensed medicines, off-label use or evidence-based. Which is most important?

Bonati M, Jacqz-Aigrain E, Choonara I.

Arch Dis Child. 2017 Jan;102(1):53-54. doi: 10.1136/archdischild-2016-311527. Epub 2016 Aug 17. No abstract available.

PMID:
27535476
45.

[Dosing regimens of antibiotics in neonates: Variations in clinical practice and what should be done?].

Leroux S, Zhao W, Biran V, Jacqz-Aigrain E.

Arch Pediatr. 2016 Sep;23(9):966-73. doi: 10.1016/j.arcped.2016.06.002. Epub 2016 Jul 19. French.

PMID:
27451383
46.

Neonatal adverse drug reactions: an analysis of reports to the French pharmacovigilance database.

Kaguelidou F, Beau-Salinas F, Jonville-Bera AP, Jacqz-Aigrain E.

Br J Clin Pharmacol. 2016 Oct;82(4):1058-68. doi: 10.1111/bcp.13034. Epub 2016 Jul 24.

47.

Pharmacokinetics and tissue diffusion of ganciclovir in mice and rats.

Boujemla I, Fakhoury M, Nassar M, Adle-Biassette H, Hurteaud MF, Jacqz-Aigrain E, Gressens P, Teissier N.

Antiviral Res. 2016 Aug;132:111-5. doi: 10.1016/j.antiviral.2016.05.019. Epub 2016 May 31.

48.

Clinical Utility and Safety of a Model-Based Patient-Tailored Dose of Vancomycin in Neonates.

Leroux S, Jacqz-Aigrain E, Biran V, Lopez E, Madeleneau D, Wallon C, Zana-Taïeb E, Virlouvet AL, Rioualen S, Zhao W.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):2039-42. doi: 10.1128/AAC.02214-15. Print 2016 Apr.

49.

Pharmacodynamics of vancomycin for CoNS infection: experimental basis for optimal use of vancomycin in neonates.

Ramos-Martín V, Johnson A, Livermore J, McEntee L, Goodwin J, Whalley S, Docobo-Pérez F, Felton TW, Zhao W, Jacqz-Aigrain E, Sharland M, Turner MA, Hope WW.

J Antimicrob Chemother. 2016 Apr;71(4):992-1002. doi: 10.1093/jac/dkv451. Epub 2016 Jan 10.

50.

Evaluation of a pediatric liquid formulation to improve 6-mercaptopurine therapy in children.

Tiphaine Ade B, Hjalgrim LL, Nersting J, Breitkreutz J, Nelken B, Schrappe M, Stanulla M, Thomas C, Bertrand Y, Leverger G, Baruchel A, Schmiegelow K, Jacqz-Aigrain E.

Eur J Pharm Sci. 2016 Feb 15;83:1-7. doi: 10.1016/j.ejps.2015.12.002. Epub 2015 Dec 2.

PMID:
26657824

Supplemental Content

Loading ...
Support Center